Faculty Collaboration Database

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv 2019 Sep 10;3(17):2581-2585

Date

09/06/2019

Pubmed ID

31484635

Pubmed Central ID

PMC6737418

DOI

10.1182/bloodadvances.2019000614

Scopus ID

2-s2.0-85072206849 (requires institutional sign-in at Scopus site)   23 Citations

Abstract

HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

Author List

Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ, Chu H, Rashidi A

Authors

Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin
Wael Saber MD, MS Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Cyclophosphamide
HLA Antigens
Hematopoietic Stem Cell Transplantation
Histocompatibility
Humans
Retrospective Studies
Siblings
Tissue Donors
Transplantation, Haploidentical